rurioctocog alfa pegol

DRUG2 trials

Sponsors

Spanish Society of Thrombosis and Haemostasis, Sanofi

Conditions

Factor VIII DeficiencyHemophiliaHemophilia A

Phase 1

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

CompletedNCT05042440

SanofiHemophilia A

Start: 2021-08-11End: 2021-11-24Updated: 2025-09-18

Unknown Phase

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

CompletedNCT03006965

Spanish Society of Thrombosis and HaemostasisFactor VIII Deficiency, Hemophilia, Hemophilia A

Start: 2016-11-11End: 2022-12-22Updated: 2023-06-08

Related Papers

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

The Journal of Clinical Pharmacology2025-03-231 citations

Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies

Haemophilia2025-03-183 citations

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.

2023-05-139 citations